Investigations into the Anti-inflammatory Effect of Bifonazole

  • H. Petri
  • H. Tronnier
  • P. Haas

Abstract

As an azole antifungal agent, the imidazolyl derivative bifonazole has a broad and characteristic range of antimycotic activity. The mechanism of action suggested for this substance is that it inhibits the biosynthesis of ergosterol, which is specifically found in azoles and has a negative effect on the synthesis of the cytoplasmic membrane of fungal cells. In vitro and in vivo tests showed pronounced fungicidal activity against dermatophytes and an intradermal activity of 50–60 h, while in clinical use bifonazole proved highly effective, in particular, against exudative ringworm lesions. Our study was therefore aimed at determining whether bifonazole had any anti-inflammatory activity. In an uncontrolled observation study histamine was used to induce an allergic reaction in ten subjects pretreated for 2 h and for 2 and 12 h on 28 cm2 skin with bifonazole, hydrocortisone and bifonazole basic cream and on an untreated control patch. Wheal and flare sizes were evaluated planimetrically after 15, 30, 60 and 90 min.

In the histamine wheal test bifonazole and hydrocortisone showed an anti-inflammatory activity — in particular 15 and 30 min after triggering of the allergic reaction; wheal and flare surfaces were significantly smaller than the areas treated with the basic cream or left untreated. The two modes of application — pretreatment 2 h or 2 and 12 h before triggering of the allergic reaction — were not followed by any differences in the sizes of the wheals and flares. Additional studies, e.g. vasoconstriction and UV erythema tests, for evaluation of the anti-inflammatory activity of bifonazole, are presently being conducted in our clinic. As soon as the first results are available we shall report on them.

Keywords

Europe Hydrocortisone Syringe Flare Histamine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Barug D, Bastiaanse HB (1983) An evaluation of the antifungal effect of Bifonazole. Arzneim Forsch/Drug Res 33: 524–528Google Scholar
  2. 2.
    Berg D, Plempel M (1984) Bifonazole, a biochemist’s view. Dermatiologica 169: Suppl 1, pp 3–10CrossRefGoogle Scholar
  3. 3.
    Datz B, Esche U, Schule ED, Kuhl B (1985) Wirksamkeit von Miconazol- und Bifonazol-Creme bei einmal täglicher Anwendung. Fortschr Med 103, 17: 464–466PubMedGoogle Scholar
  4. 4.
    Döring HF (1984) Treatment of sebopsoriasis - a clinical trial. Dermatologica 169/51/84: 125–134Google Scholar
  5. 5.
    Döring HF, Ilgner M (1982) Externe Therapie der Roazea mit Imidazolderivaten. Vortrag auf der Gemeinschaftstagung der Rhein-Westf. und Südwestdt. DermatologenGoogle Scholar
  6. 6.
    Meisel C (1985) Mycosportherapie verschiedener Hautmykosen. Pilze. GIT Suppl. 5 (5): 11–18Google Scholar
  7. 7..
    Plempel M (1986) Persönliche MitteilungGoogle Scholar
  8. 8.
    Plempel M, Berg D (1984) Reduction of the in vivo virulence of Candida albicans by pretreatment with subinhibitory azole concentration in vivo. Dermatologica 169, suppl 1: 11–18CrossRefGoogle Scholar
  9. 9.
    Plempel M, Regel E (1982) Antimycotic properties of the topical azole bifonazole in vivo and in vitro. In: Urabe H, Zaias N, Stettendorf S: International Antifungal Symposium: Bifonazole. Excerpta Medica, Amsterdam, 29–36Google Scholar
  10. 10.
    Reinel D (1985) Lokaltherapie von Dermatomykosen. Z Allgem Med 23: 835–838Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • H. Petri
    • 1
  • H. Tronnier
    • 1
  • P. Haas
    • 1
  1. 1.Department of DermatologyMunicipal ClinicsDortmundFederal Republic of Germany

Personalised recommendations